Table 1.
Baseline Characteristics of the Study Cohort.
| Variables | n = 260 |
|---|---|
| Age (years), median (95%CI) | 62.0 (61.0–63.2) |
| PSA (ng/ml), median (95%CI) | 5.6 (5.32–5.95) |
| PSA density (ng/ml/cc), median (95%CI) | 0.12 (0.10–0.13) |
| Total Number of cores, median (95%CI) | 12.0 (12.0–14.0) |
| Positive cores, n (%) | |
| 1 | 137 (52.7) |
| 2 | 123 (47.3) |
| Clinical stage, n (%) | |
| cT1c | 231 (88.85) |
| cT2 | 29 (11.15) |
| Pathological stage, n (%) | |
| pT2 | 189 (72.69) |
| pT3a | 68 (26.15) |
| pT3b | 3 (1.15) |
| Pathological lymph node, n (%) | |
| N1 | 1 (0.38) |
| N0 | 38 (14.62) |
| Nx | 221 (85.0) |
| Pathological Gleason Score, n (%) | |
| ISUP 1 | 166 (63.8) |
| ISUP 2 | 75 (28.8) |
| ISUP 3 | 17 (6.6) |
| ISUP 4 | 2 (0.8) |
| NLR, median (IQR) | 2.07 (1.67–2.66) |
| PLR, median (IQR) | 114.83 (93.89–136.3) |
| LMR, median (IQR) | 3.69 (3.03–4.43) |
95%CI = 95% confidence interval for median; NLR = neutrophil-to-lymphocyte ratio; PLR = platelets-to-lymphocyte ratio; LMR = lymphocyte-to-monocyte ratio; ISUP = International Society of Urological Pathology.